Vanta Bioscience logo

Vanta Bioscience financials: balance sheet, profit and loss, cash flow

BSE: 540729Healthcare ServicesSmall Cap

Vanta Bioscience Limited · Face value ₹10 · Listed Oct 2017
Last close ₹20.39down ₹0.01 (0.05%)

Share price at the BSE close on 30 Oct 2026. Previous close ₹20.40.

30 Oct: open ₹20.39, high ₹20.39, low ₹20.39

52-week range of traded prices to 30 Oct 2026
₹14.71Low, 24 Mar 2026₹29.00High, 6 Nov 2025
Market cap
₹15 Cr4,396th largest listed
P/E
133.90
P/B
0.68
Dividend yield
Nonein the last 12 months
ROE
0.7%
Debt to equity
1.80
Volume, BSE
750

Vanta Bioscience's financial statements for the 9 years to Mar 2026, standalone: the listed company alone, without its subsidiaries.

9 years at a glance

₹ crore, years to March.Vanta Bioscience annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
4.00.0Mar 18120.712Mar 19141.012Mar 20100.513Mar 219.30.117Mar 225.2−4.226Mar 238.60.125Mar 241.1−2.830Mar 251.80.138Mar 26
Peak revenue ₹14 Cr, year to Mar 2020; lowest ₹1.13 Cr, year to Mar 2025Back to profit in the year to Mar 2026, ₹0.12 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
103.1%−246.5%25.9%36.4%26.7%42.7%−146.9%103.1%0.7%5.6%6.9%4.7%0.8%−81.9%0.6%−246.5%6.6%Mar 18Mar 20Mar 22Mar 24Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue1.8
  2. Operating expenses+0.1
  3. Operating profit1.9
  4. Depreciation−1.2
  5. Other income+0.2
  6. Finance costs−0.8
  7. Profit before tax0.0
  8. Tax+0.1
  9. Net profit0.1

What the company owns

  • Plant, investments and other assets₹56 Cr
  • Inventory₹8 Cr
  • Receivables₹3 Cr
  • Cash and bank₹0 Cr

What pays for it: net worth and liabilities

  • Borrowings₹38 Cr
  • Net worth₹21 Cr
  • Other liabilities₹5 Cr
  • Owed to suppliers₹2 Cr

Profit and loss

Standalone, ₹ crore, years to March.Vanta Bioscience half-yearly results

₹ croreMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 1 AugMar 2026Filed 30 May
Revenue from operations4.012.414.110.09.35.28.61.11.8
3.0–––5.93.84.92.8−0.1
Materials and goods bought0.31.41.20.80.60.70.31.1−0.9
Employee costs1.6–––3.0–2.70.6–
Other expenses1.0–––2.3–2.01.1–
Operating profit before depreciation1.0–––3.41.43.7−1.71.9
Operating margin25.9%–––36.4%26.7%42.7%−146.9%103.1%
Materials, % of revenue8.1%–––6.7%–3.1%94.3%–
Employee costs, % of revenue40.4%–––32.0%–31.3%51.7%–
Other expenses, % of revenue25.6%–––25.0%–22.9%100.9%–
Depreciation and amortisation0.6–––1.33.11.20.41.2
Operating profit after depreciation0.5–––2.1−1.72.4−2.10.6
Other income0.10.20.10.00.20.60.00.00.2
Finance costs0.21.71.92.12.13.12.40.70.8
Profit before tax0.31.11.30.60.1−4.20.0−2.70.0
0.30.40.30.10.10.00.00.1−0.1
Net profit0.00.71.00.50.1−4.20.1−2.80.1
Net margin0.7%5.6%6.9%4.7%0.8%−81.9%0.6%−246.5%6.6%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2023 and Mar 2026 they do not, so they are left blank. Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2019, Mar 2020 and Mar 2021: the statement does not state its depreciation, which operating profit is worked out from, so operating profit is not given.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 1 AugMar 2026Filed 30 May
22.223.423.924.019.719.817.121.3
Share capital6.36.36.36.36.36.36.37.1
Reserves15.917.117.617.713.413.510.814.1
12.212.313.317.125.825.430.538.1
3.27.110.813.510.214.218.611.8
12.611.011.512.921.718.920.133.1
Total assets38.041.646.250.451.652.955.866.1
23.924.132.739.440.540.945.451.1
14.117.513.511.011.112.010.415.0
Net debt9.912.213.217.125.725.230.337.9
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 1 AugMar 2026Filed 30 May
11.06.30.64.50.6−5.2
10.66.30.64.50.6−5.2
6.72.80.50.92.2−7.3
Receivables−0.61.3−1.2−0.40.6−0.8
Inventories4.22.50.1−0.31.0−1.0
Payables0.00.20.00.00.00.0
Other working capital3.1−1.21.61.60.6−5.4
Capital spending0.90.32.50.00.80.0
Free cash flow10.16.0−1.94.5−0.2−5.2
−9.9−8.1−2.5−1.7−5.0−6.9
−1.21.71.9−2.84.412.1
Dividends paid0.00.00.00.00.00.0
Shares issued0.00.00.00.00.0–
Net change in cash0.00.00.00.10.00.0
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2018, Mar 2019 and Mar 2020. Shares issued is left blank for the year to Mar 2026: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 1 AugMar 2026Filed 30 May
Earnings per share₹0.05₹1.17₹1.55₹0.75₹0.12−₹6.71₹0.08−₹4.21₹0.17
Diluted earnings per share₹0.05₹1.17₹1.55₹0.75₹0.12−₹6.71₹0.08−₹4.21₹0.17
Book value per share–₹35.24₹37.14₹37.88₹38.01₹31.28₹31.36₹27.14₹29.88
Shareholder yield–––0.0%0.0%0.0%0.0%0.0%–
Market cap at the year end (₹ crore)2988571036936401411
Shareholder yield is left blank for the year to Mar 2026: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Ratios

Standalone, years to March.Vanta Bioscience PE ratio and valuation

RatioMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 1 AugMar 2026Filed 30 May
Revenue growth–211.7%13.6%−28.9%−6.9%−44.7%65.5%−86.8%61.1%
Operating profit growth–––––−59.4%164.5%––
Net profit growth–2,469.6%41.0%−51.9%−83.3%––––
Earnings per share growth–2,240.0%32.5%−51.9%−83.9%––––
–3.1%4.3%2.0%0.3%−19.4%0.3%−15.1%0.6%
––1.2 pts−2.3 pts−1.7 pts−19.7 pts19.6 pts−15.3 pts15.7 pts
From the net margin––0.8 pts−1.4 pts−1.6 pts−32.3 pts19.5 pts−107.0 pts15.5 pts
From asset turnover––0.3 pts−1.0 pts−0.1 pts15.2 pts0.1 pts93.2 pts0.2 pts
From borrowing––0.1 pts0.1 pts0.0 pts−2.6 pts0.0 pts−1.5 pts0.0 pts
Return on capital employed––––5.1%−3.8%5.3%−4.4%1.1%
Cash conversion–––2,340.8%8,086.8%–8,901.4%–−4,356.7%
Interest cover2.3–––1.0–1.0–0.8
Debt to equity–0.550.530.560.711.301.281.781.79
Receivable days–46357228136100565514
Inventory days–2,4144,3364,3524,2383,82710,2822,226−3,078
Payable days–––––––925−631
Cash conversion cycle, days–––––––1,866−1,933
Working capital days–254314186964052118942,012
Asset turnover–0.330.350.230.190.100.160.020.03
Assets per rupee of net worth–1.711.741.862.022.332.642.953.18
Sales per rupee of plant–0.580.680.340.260.140.230.100.19
Capital spending to depreciation––––0.250.810.011.790.01
Interest cover is left blank for the years to Mar 2023 and Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the year to Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
0.2%
Cash from operations against operating profit
−278.6%
Measure10 years5 years3 years
Revenue growth, yearly rate–−29.0%−29.4%
Profit growth, yearly rate–−23.9%–
Return on equity, average–−6.6%−4.7%
Return on capital employed, average–0.7%0.7%
Operating margin, average–12.4%−0.3%
Net margin, average−33.6%−64.1%−79.8%
Asset turnover, average–0.100.07
Cash conversion cycle, days, average––−34
Interest cover, average––0.9
Debt to equity, average–1.371.62

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations6.9−0.1−5.2
Cash from investing−24.1−13.5−6.9
Cash from financing17.313.712.1
Capital spending3.70.80.0
Dividends paid0.00.00.0
Borrowings raised13.913.98.9
Borrowings repaid0.00.00.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Effective tax ratePublished threshold 17.16 per cent91.43––––––––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
6 Oct 2026India Ratings and Research Private LimitedBank loan facilitiesLong-term scaleIND D(NCO)Maintained in non-cooperating category21.01
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.